Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer.
Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer.
复制标题
DOI：
10.3390/cancers13061281
复制
发表时间：
2021-03-13
期刊：
影响因子：
5.2
通讯作者：
Pagès F
中科院分区：
文献类型：
--
作者：
El Sissy C;Kirilovsky A;Zeitoun G;Marliot F;Haicheur N;Lagorce-Pagès C;Galon J;Pagès F
除了tnm分期系统，还需要生物标志物来指导癌症治疗。我们提供了免疫评分的概述，这是一种标准化的免疫分析，基于肿瘤组织中CD3+和CD8+细胞毒性T细胞的数字病理学定量。我们讨论了免疫评分（IS）和活检适应的IS （ISB）生物标志物在预测结肠癌和直肠癌的临床结果和治疗反应方面的有用性。从首次证明淋巴细胞浸润在直肠癌中的独立预后价值，到国际指南首次推荐使用标准化免疫测定，即“免疫评分”（Immunoscore， IS），以准确预测tnm系统之外的结肠癌，需要40年的时间。标准化过程不仅包括信息系统的概念化、开发、微调和大型国际联盟的验证，还包括在世界范围内展示稳健性和可重复性，并测试国际规范及其对信息系统的影响。这是范式重大变化的第一步，现在认为癌症是相互矛盾的驱动力的结果，即肿瘤扩张和免疫反应，动态相互作用并影响预后和对治疗的反应。这促使我们在一项国际结肠癌随机队列研究中评估和证明肿瘤免疫状态的能力，正如IS所反映的那样，以准确预测化疗反应。此外，我们开发了一种衍生的IS，用于初始诊断活检（ISB），以评估对新辅助治疗的反应水平。在直肠癌中，ISB与对新辅助放化疗的组织学反应程度呈正相关，如果结合临床数据，ISB可以更准确地识别出适合无创策略的患者。基于这些结果，我们目前正在建立一个国际队列进行确认。IS与免疫疗法的潜在作用必须得到预测。
Beyond the TNM-staging system, biomarkers are needed to guide cancer treatments. We provide an overview of the Immunoscore, a standardized immune assay based on quantification by digital pathology of CD3+ and CD8+ cytotoxic T cells in tumor tissues. We discuss the usefulness of the Immunoscore (IS) and biopsies-adapted IS (ISB) biomarkers for prediction of clinical outcome and treatment response in colonic and rectal cancers. Four decades were needed to progress from the first demonstration of the independent prognostic value of lymphocytes infiltration in rectal cancers to the first recommendation from the international guidelines for the use of a standardized immune assay, namely the “Immunoscore” (IS), to accurately prognosticate colon cancers beyond the TNM-system. The standardization process included not only the IS conceptualization, development, fine-tuning, and validation by a large international consortium, but also a demonstration of the robustness and reproducibility across the world and testing of international norms and their effects on the IS. This is the first step of a major change of paradigm that now perceives cancer as the result of contradicting driving forces, i.e., the tumor expansion and the immune response, interacting dynamically and influencing the prognosis and the response to therapies. This prompted us to evaluate and evidence the capacity of the tumor immune status, as reflected by the IS, to accurately predict chemotherapy responses in an international, randomized cohort study of colon cancer. Moreover, we developed a derived IS performed on initial diagnostic biopsies (ISB) to assess response levels to neoadjuvant therapies. In rectal cancer, ISB was positively correlated with the degree of histologic response to neoadjuvant chemoradiotherapy and identified - alone and even more accurately if combined with clinical data- patients eligible for a noninvasive strategy. Based on these results, we are currently setting up an international cohort for confirmation. The potential role of IS with immunotherapies must be anticipated.
登录
查看更多内容
DOI：
10.6004/jnccn.2020.0032
发表时间：
2020-07-01
影响因子：
13.4
作者：
Benson, Al B., III;Venook, Alan P.;Gurski, Lisa A.
通讯作者：
Gurski, Lisa A.
DOI：
10.1056/nejmoa1713709
发表时间：
2018-03-29
期刊：
The New England journal of medicine
影响因子：
--
作者：
Grothey A;Sobrero AF;Shields AF;Yoshino T;Paul J;Taieb J;Souglakos J;Shi Q;Kerr R;Labianca R;Meyerhardt JA;Vernerey D;Yamanaka T;Boukovinas I;Meyers JP;Renfro LA;Niedzwiecki D;Watanabe T;Torri V;Saunders M;Sargent DJ;Andre T;Iveson T
通讯作者：
Iveson T
影响因子：
5.6
作者：
Dayde D;Tanaka I;Jain R;Tai MC;Taguchi A
通讯作者：
Taguchi A
影响因子：
3.4
作者：
JASS, JR
通讯作者：
JASS, JR
影响因子：
35.7
作者：
Araghi, Marzieh;Soerjomataram, Isabelle;Arnold, Melina
通讯作者：
Arnold, Melina